Press Releases September 14, 2026 06:32 PM

Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Health Catalyst Grants Significant Inducement RSUs to New CEO Simeon Kohl

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
HCAT

Health Catalyst, Inc. announced the grant of 2,747,385 restricted stock units to its newly appointed CEO Simeon Kohl as inducement awards under Nasdaq listing rules. The equity grants aim to incentivize Mr. Kohl's leadership and align his interests with the company's growth objectives. Mr. Kohl also purchased shares on the open market recently, demonstrating confidence in the company's future.

Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
HCAT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Health Catalyst appointed Simeon Kohl as CEO and President effective September 14, 2026.
  • The Compensation Committee granted 2.75 million RSUs as inducement awards under Nasdaq rules, vesting over time based on continued employment.
  • Simeon Kohl recently acquired 59,000 shares of the company in open market purchases, signaling personal investment in Health Catalyst's success.

SALT LAKE CITY, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst” or the “Company,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that on September 14, 2026, the Compensation Committee of the Company’s Board of Directors granted 2,747,385 restricted stock units (the “RSUs”) to Simeon Kohl under the Health Catalyst, Inc. 2026 Employment Inducement Incentive Plan (the “Inducement Plan”) in connection with Mr. Kohl’s previously announced appointment as Chief Executive Officer and President of the Company effective on September 14, 2026. The awards were granted as inducement material to Mr. Kohl’s entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Of the 2,747,385 RSUs granted to Mr. Kohl, 915,975 RSUs will vest on September 14, 2027 and the remaining RSUs will vest in eight approximately equal quarterly installments, in each case subject to Mr. Kohl’s continued employment with the Company on such vesting date. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of the RSU agreement covering the grant.

The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees or directors of the Company or its subsidiaries, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4).

On September 11, 2026 and September 14, 2026, Mr. Kohl acquired an aggregate of 59,000 shares of Health Catalyst's common stock through open market purchases with a weighted average price of $1.787188 per share.

About Health Catalyst

Health Catalyst, Inc. (Nasdaq: HCAT) is a healthcare intelligence company designed to accelerate measurable improvement for health systems across cost, clinical, and consumer performance. Backed by deep domain expertise, proprietary AI-driven technology, and $2.8 billion in documented outcomes, Health Catalyst helps health systems move from data to confident, measurable action.

Health Catalyst Investor Relations Contact
Stephanie St. Clair
Finance and Investor Relations, SVP
+1 (855)-309-6800
[email protected]

Health Catalyst Media Contact
Kay Blazar
VP, PR
SVM PR & Marketing
[email protected]


Risks

  • The large number of RSUs granted may cause dilution concerns among existing shareholders.
  • The success of the company heavily depends on the new CEO's ability to execute growth strategies effectively.
  • Stock price volatility could be influenced by market perception of management changes and associated equity incentives.

More from Press Releases

Einride and Lidl Launch First Autonomous Cab-less Truck on German Public Road Sep 15, 2026 Piedmont Realty Trust Announces Pricing of $200,000,000 Exchangeable Senior Notes Offering Sep 14, 2026 VPG Foil Resistors Partners with Source Technologi to Expand Footprint in India’s Aerospace & Defense, Telecom, and Semiconductor Sectors Sep 14, 2026 IHT RECEIVES NYSE-AMERICAN APPROVAL FOR COMPLIANCE PLAN; REVERSE MERGER DISCUSSIONS CONTINUE Sep 14, 2026 CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited) Sep 14, 2026